NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/01/2026
Voltar para busca
Dado oficial do USPTO
RENMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
06/01/2026
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
31/07/2019
Data de registro
06/01/2026
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/01/2026
Última transação
06/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
01/06/2020
Primeiro uso no comércio
01/06/2020
Código do desenho
4
Tipo de titular
99
Localização do titular
Daxing District, Beijing, CN
Examinador
CROWLEY, SEAN MICHAEL
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Beijing Biocytogen Co., Ltd.
Representantes
CYNTHIA JOHNSON WALDEN Fish & Richardson P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancerantibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposesfor the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseasesActive Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparationantibodies and proteins for biopharmaceuticals derived from experimental animals
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
06/01/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
18/12/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
18/12/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
14/11/2025
IUAF
USE AMENDMENT FILED
13/11/2025
EISU
TEAS STATEMENT OF USE RECEIVED
13/11/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
27/10/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/10/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/10/2025
EX1G
SOU EXTENSION 1 GRANTED
01/10/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/10/2025
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2025
DRRR
DIVISIONAL REQUEST RECEIVED
18/05/2025
EXT1
SOU EXTENSION 1 FILED
18/05/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
18/05/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/05/2025
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
01/05/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
19/11/2024
TMBN
TTAB RELEASE CASE TO TRADEMARKS
21/10/2024
OP.T
OPPOSITION TERMINATED NO. 999999
21/10/2024
OP.D
OPPOSITION DISMISSED NO. 999999
21/10/2024
OP.I
OPPOSITION INSTITUTED NO. 999999
14/02/2022
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
15/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/08/2021
PUBO
PUBLISHED FOR OPPOSITION
17/08/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/07/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
17/02/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
05/01/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
05/01/2021
CNSI
SUSPENSION INQUIRY WRITTEN
05/01/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/12/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
29/05/2020
GNSL
LETTER OF SUSPENSION E-MAILED
29/05/2020
CNSL
SUSPENSION LETTER WRITTEN
29/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2020
ALIE
ASSIGNED TO LIE
08/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/05/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/11/2019
GNRT
NON-FINAL ACTION E-MAILED
05/11/2019
CNRT
NON-FINAL ACTION WRITTEN
05/11/2019
DOCK
ASSIGNED TO EXAMINER
28/10/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/08/2019
NWAP
NEW APPLICATION ENTERED
03/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RENMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.